What it is
Nabla Bio's JAM ('Joint Atomic Modeling') system designs epitope-specific antibodies — including against notoriously difficult multi-pass membrane proteins like GPCRs — with high specificity and developability, largely in silico. It spun out of the Wyss Institute at Harvard.
Evidence trail
BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.
Model passport
How Nabla Bio — JAM represents biology
Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.
Biological scale
Modalities & tasks
Registry, claims and frontier intelligence
Version history not yet curated
1 version record · release year not yet normalized. Model-family identity remains separate from capability and access changes.
Explore version lineage →0 normalized claims
No task, dataset, split and metric claim has been normalized for this record yet.
Open claim intelligence →0 connected frontiers
No frontier-research record currently connects to this model.
Inspect research horizon →Inputs and outputs
Inputs
Antigen, sequence or desired propertiesOutputs
Antibody candidatesAffinity or developability estimatesScientific and technical profile
Scientific principles
Technology
Scientific lineage
These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.
Hybridoma production of monoclonal antibodies
Georges J. F. Köhler & César MilsteinTherapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.
Selective toxicity and the ‘magic bullet’
Paul EhrlichTarget selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.
Anfinsen’s dogma—the thermodynamic hypothesis
Christian B. AnfinsenProtein structure prediction, inverse folding and generative protein design all assume that sequence strongly constrains structure and function.
Somatic gene rearrangement generates antibody diversity
Susumu TonegawaAntibody language models and repertoire design operate on the sequence space created by V(D)J recombination and somatic diversification.
Phage display and selection of binding proteins
George P. Smith & Sir Gregory P. WinterDisplay-based selection created an experimental search engine for protein binders and remains a core validation partner for computational antibody design.
Lock-and-key molecular recognition
Emil FischerThe metaphor seeded structure-based ligand design, pharmacophore thinking and the search for complementary binding pockets.
Evaluation evidence
BioAtlas has not yet extracted a structured benchmark claim for this record.
Known limitations
- Independent reproducibility is limited by proprietary access.
- A structured benchmark claim has not yet been extracted for this record.
- Outputs require task-specific scientific and experimental validation.
Milestones
Targets multi-pass membrane proteins directly.
Spun out of Harvard's Wyss Institute.